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Background: Irinotecan is a camptothecin analogue currently used in clinical practice to treat advanced colorectal
cancer. However, acquired resistance mediated by the drug efflux pump ABCG2 is a recognized problem. We reported
on a novel camptothecin analogue, FL118, which shows anticancer activity superior to irinotecan. In this study, we
sought to investigate the potency of FL118 versus irinotecan or its active metabolite, SN-38, in both in vitro and in vivo
models of human cancer with high ABCG2 activity. We also sought to assess the potency and ABCG2 affinity of several
FL118 analogues with B-ring substitutions.
Methods: Colon and lung cancer cells with and without ABCG2 overexpression were treated with FL118 in the
presence and absence of Ko143, an ABCG2-selective inhibitor, or alternatively by genetically modulating ABCG2
expression. Using two distinct in vivo human tumor animal models, we further assessed whether FL118 could
extend time to progression in comparison with irinotecan. Lastly, we investigated a series of FL118 analogues
with B-ring substitutions for ABCG2 sensitivity.
Results: Both pharmacological inhibition and genetic modulation of ABCG2 demonstrated that, in contrast to
SN-38, FL118 was able to bypass ABCG2-mediated drug resistance. FL118 also extended time to progression in
both in vivo models by more than 50% compared with irinotecan. Lastly, we observed that FL118 analogues with
polar substitutions had higher affinity for ABCG2, suggesting that the nonpolar nature of FL118 plays a role in
bypassing ABCG2-mediated resistance.
Conclusions: Our results suggest that in contrast to SN-38 and topotecan, FL118 is a poor substrate for ABCG2
and can effectively overcome ABCG2-mediated drug resistance. Our findings expand the uniqueness of FL118
and support continued development of FL118 as an attractive therapeutic option for patients with drug-refractory
cancers resulting from high expression of ABCG2.
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Camptothecin analogues have been used clinically to treat
cancer for almost 20 years. Irinotecan (also known as CPT-
11) is used in combination with other antitumor agents as
a first-line therapy for metastatic colorectal cancer [1] and
has a history of use as a second-line therapy in advanced
gastric and non-small cell lung cancers (NSCLC) [2,3]. The
second clinically used camptothecin analogue, topotecan, is
approved for treatment of ovarian, cervical, and small cell
lung cancers [1]. It has been established in the literature
that camptothecin analogues function through inhibition of
the topoisomerase I (Top1) enzyme. Camptothecin-class
compounds target the DNA-Top1 covalent complex, form-
ing a ternary complex that prevents the dissociation of
Top1. This ternary complex inhibits replication and tran-
scription and leads to the formation of double-strand DNA
breaks [4,5].
Unfortunately, resistance to irinotecan and topotecan
is observed in the clinic. Failure of irinotecan- and
topotecan-based regimens has been hypothesized to
occur through a number of different mechanisms,
though only a few are supported with clinical data. In
vitro evidence and limited clinical observations suggest
mutations in the Top1 gene decrease the affinity of the
Top1 protein with clinically used camptothecin ana-
logues [6,7]. However, based on the literature, likely a
more common cause of resistance to irinotecan and
topotecan is the increased expression of ATP-binding
cassette (ABC), subfamily G, isoform 2 protein (ABCG2,
also known as breast cancer resistance protein, BCRP), a
drug efflux pump and a member of the ABC transporter
superfamily [8]. A number of clinical studies revealed
that failure of irinotecan and topotecan often correlates
with increased ABCG2 expression [9,10]. Multiple
in vitro studies have demonstrated that irinotecan, SN-
38 (active metabolite of irinotecan), and topotecan areTable 1 EC50 of FL118 and SN-38 in NSCLC and colorectal c
HCT116 sub-lines
Cancer type Cell line FL118 EC50 (95%CI) (nM)
NSCLC H460 0.31 (0.21-0.47)
EKVX 0.56 (0.38-0.83)
A549 0.86 (0.61-1.22)







95% CI = 95% confidence interval.
RP = Relative potency, calculated by dividing the EC50 of SN-38 by the EC50 of FL1
RR = Relative resistance, calculated by dividing the EC50 of indicated drug in resistaall substrates for ABCG2, and high expression of
ABCG2 is associated with decreased intracellular accu-
mulation of these compounds and consequentially a de-
crease in drug potency [11,12]. Additionally, many other
anticancer agents are known ABCG2 substrates, includ-
ing methotrexate [13], many anthracyclines [14], and a
variety of tyrosine kinase inhibitors [15,16].
Our lab recently reported on a novel camptothecin de-
rivative, designated FL118 [17,18]. The chemical name
of FL118 is 10,11-methylenedioxy-20(S)-camptothecin,
also known as 10,11-MD-CPT, MDCPT [19], and 10,11-
mCPT [20] (Additional file 1: Figure S1). FL118 shows
strong anticancer activity in several different cancer
types in vitro and in vivo [17,18]. We have demonstrated
that although FL118 is not a better Top1 inhibitor than
clinically used camptothecin analogues [17,18], FL118 is
able to selectively inhibit the expression of several mem-
bers of the Inhibitor of Apoptosis family (survivin, XIAP,
and cIAP2) and the Bcl-2 family (Mcl-1), which was
demonstrated to contribute to FL118 function and anti-
cancer activity [18,21]. More recent studies have further
characterized the novel properties of FL118. Induction
of cancer cell senescence and cell death by FL118 em-
ploys both p53-dependent and p53-independent signal-
ing pathways, and rapid induction of wild type p53
accumulation by FL118 is largely independent of the
ATM-dependent DNA damage signaling pathway but
dependent on E3-competent Mdm2 [22]. Our previous
studies also revealed that, while mice showed continuing
body weight loss after treatment with irinotecan, body
weight rapidly recovers after the completion of FL118
treatment [18,21], suggesting that FL118 possesses a more
favorable toxicity profile in comparison with irinotecan.
In the present study we found that, although SN-38
and topotecan are ABCG2 substrates and fail to over-
come ABCG2-mediated drug resistance, FL118 isancer cell lines, including Top1 inhibitor-resistant







7.63 (6.14-9.48) 3.3 6.3 2.4
20.3 (13.9-29.6) 4.9 11.5 6.4
135 (80.4-226) 33.4 11.2 42.9
51.5(37.4-70.8) 24.2 5.9 16.3
18.
nt cell line by EC50 in parental cell line.
Westover et al. Molecular Cancer  (2015) 14:92 Page 3 of 11insensitive to ABCG2 expression and effectively bypasses
ABCG2 resistance. FL118 also demonstrates better anti-
tumor efficacy than irinotecan in human xenografts with
high ABCG2 expression. Additionally, we found that the
relatively nonpolar nature of FL118 plays a role in
bypassing ABCG2-induced resistance.
Results
FL118 is a more potent anticancer agent than SN-38 in
NSCLC and colon cancer cell lines
The potency of FL118 versus SN-38 was compared in a
panel of NSCLC and colon cancer cell lines. In each of the
parental cell lines tested, FL118 was 5- to 10-fold more po-
tent than SN-38, with EC50 values consistently below 1 nM
(Table 1, Additional file 1: Figures S2, S3). In the four
HCT116-derived camptothecin-resistant colon cancer sub-
lines, each with mutations in Top1 was demonstrated to de-
crease potency of camptothecin analogues [7], FL118
showed greater potency than SN-38 overall. Intriguingly,
FL118 showed much more potency than SN-38 in sublines
SN50 and A2 in comparison with sublines SN6 and G7Figure 1 Pharmacological inhibition of ABCG2 modulates the potency of S
expression in HCT116 colon cancer cells, drug-resistant HCT116 sub-lines (A
in the presence and absence of 1 μM Ko143, an ABCG2 inhibitor, after 72
and F, dose-response curves in the presence and absence of 1 μM Ko143
(F). Viability for each dose was determined using a ViCELL XR cell viability
n = 3 independent experiments.(Table 1). SN50 and A2 sublines highly express ABCG2,
while the SN6 and G7 sublines show undetectable ABCG2
expression (Figure 1A). We assessed whether there was a
difference between relative resistance (RR) for FL118 and
SN-38 in HCT116 sublines. We back-transformed RR into
LogRR for the purpose of statistical analysis, and found a
statistically significant difference in three sublines tested
(SN6, SN50, A2). Importantly, the difference between the
LogRR of FL118 and SN-38 was statistically significant in
both sublines with high ABCG2 expression, SN50 (p =
0.023) and A2 (p = 0.027) (Additional file 1: Table S1). To-
gether, these data suggest that ABCG2 expression is an
SN-38 resistance factor but not an FL118 resistance factor.
Therefore, we hypothesized that FL118 is a comparatively
poor substrate of ABCG2, and thus the potency of FL118
is not affected by ABCG2 expression.
Pharmacological inhibition of ABCG2 does not modulate
FL118 potency
Many anticancer drugs are substrates of the ABC
transporter ABCG2, which often contributes to drugN-38, but not FL118. A and B, Western blot analysis of ABCG2 protein
), and H460 and EKVX NSCLC cells (B). C and E, dose-response curves
hour treatments in HCT116 sub-lines (C) and NSCLC cell lines (E). D
after 72-hour treatments in HCT116 sub-lines (D) and NSCLC cell lines
analyzer and normalized to that of DMSO control. Error bars = SEM,
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FL118 potency is affected by ABCG2 activity, we utilized
cell lines with varying ABCG2 protein expression to test
drug sensitivity. In addition to the camptothecin-resistant
HCT116 sublines discussed above, we also employed two
NSCLC cell lines: H460, which express high levels of
ABCG2 protein [10,23], and EKVX cells, which have un-
detectable levels of ABCG2 protein expression when
assessed by Western blot (Figure 1B). Then, we employed
a highly selective inhibitor of ABCG2, Ko143 [24], to
determine whether inhibition of ABCG2 would affect
FL118 potency in these cells. As expected, inhibition of
ABCG2 activity by Ko143 in HCT116-A2, HCT116-SN50,
and H460 cell lines, which have high ABCG2 expression,
resulted in a significant increase in potency for SN-38
(Figure 1C, E) and topotecan (Additional file 1: Figure S4),
indicating that they are substrates of ABCG2. In contrast,
the potency of FL118 remained unchanged (Figure 1D, F)
in these cell lines, suggesting that FL118 potency is un-
affected by ABCG2 overexpression. Using HCT116-SN50
as a representative example, the EC50 of SN-38 alone was
135.1 nM, compared to 12.3 nM for SN-38 in the pres-
ence of Ko143 (p < 0.0001). In the same cell line, the EC50
of FL118 alone was 4.0 nM, compared to 3.0 nM for
FL118 in combination with Ko143 (p = 0.22). In contrast,
Ko143 did not alter the potency of either SN-38 or FL118
in HCT116, HCT116-G7, or EKVX cells that lack detect-
able ABCG2 (Figure 1).
Genetic silencing or overexpression of ABCG2 does not
affect the potency of FL118
We also employed a genetic approach through direct si-
lencing of ABCG2 to test the hypothesis that FL118 po-
tency is not affected by ABCG2 expression. Two
ABCG2-specific shRNAs were validated in our studies
that effectively knock down ABCG2 protein expression
(Figure 2A). When the expression of ABCG2 was stably
knocked down in HCT116-A2 cells, the EC50 of SN-38
was reduced to 19.6 nM (p < 0.0001) and 22.4 nM (p <
0.0001), compared to 97.0 nM in cells transduced with a
non-silencing control shRNA (Figure 2B, Additional
file 1: Table S2). In contrast, consistent with pharmaco-
logical inhibition, there was no change in potency for
FL118 with or without ABCG2 silencing (Figure 2C,
Additional file 1: Table S2). Next, we alternatively deter-
mined whether exogenous overexpression of ABCG2
would affect FL118 potency using a human embryonic
kidney cell line, HEK293 that was stably transfected with
either an ABCG2 expression vector (HEK293/ABCG2)
or an empty vector (HEK293/pcDNA3) (Figure 2D). As
expected, overexpression of ABCG2 decreased the po-
tency of SN-38 from 0.39 nM in HEK293/pcDNA3 cells
to 62.95 nM in HEK293/ABCG2 cells (p = 0.002)
(Figure 2E, Additional file 1: Table S2). In contrast,there was no significant difference in FL118 potency
in HEK293/pcDNA3 cells compared to HEK293/
ABCG2 (p = 0.09) (Figure 2F, Additional file 1: Table
S2). These data confirm that ABCG2 expression
does not mediate resistance to FL118, suggesting
that FL118 could bypass ABCG2-mediated treatment
resistance.
FL118 exhibits better antitumor activity than irinotecan
and significantly extends time to progression in human
xenograft models
Next, we determined antitumor activity of FL118 versus
irinotecan in HC116-SN50 and H460 xenograft models
of ABCG2-mediated drug-resistant cancer. Once tu-
mors were established and reached an average volume
of ~100 mm3, a repeating treatment was applied intra-
peritoneally (IP) weekly for 4 weeks, followed by 1 week
of rest. The time to progression (TTP) was used as the
primary endpoint for assessment of efficacy of FL118
versus irinotecan. In both models, FL118 controlled
tumor growth better than irinotecan (Figure 3A, B) and
led to significantly improved TTP (Figure 3C, D).
Specifically, in the HCT116-SN50 model, median TTP
was 58 days for animals treated with FL118, compared to
38.5 days for animals treated with irinotecan (p = 0.002), a
50.6% increase (Figure 3C). In the H460 model, median
TTP was extended from 21 days with irinotecan to 35 days
with FL118 (p = 0.009), a 66.7% increase (Figure 3D). Con-
sistent with our earlier reports, FL118 showed a tolerabil-
ity profile similar to irinotecan (Figure 3E, F).
The unique nonpolar structure of FL118 appears to play a
role in FL118 bypassing ABCG2-mediated drug resistance.
We next investigated the potency of several analogues of
FL118 with functional groups attached to the 7-position
of the B ring (Figure 4A), a position where substitutions
have been shown to favorably alter drug properties
[25,26], in the irinotecan-resistant sub-line HCT116-
SN50. We observed little change in potency between
FL118 and the FL118-derived analogues with relatively
nonpolar alkyl substitutions (methyl, ethyl, and allyl)
(Table 2). In contrast, addition of more polar groups
(bromomethyl, chloromethyl, and hydroxymethyl) re-
sulted in a marked decrease in potency (Table 2). Thus,
adding groups to the B ring that increase the polarity of
the molecule would result in decreased potency. Previ-
ous reports indicated that the addition of polar residues
to the A ring of camptothecin analogues increased affinity
to ABCG2 [27,28], but the effect of B ring substitutions
with these types of residues remains unknown. To assess
whether the polarity-related decrease in potency was at
least partially dependent on ABCG2, growth inhibition was
subsequently assessed in the presence and absence of
ABCG2 inhibitor Ko143. Although we observed no
Figure 2 Genetic silencing or overexpression of ABCG2 demonstrates that the potency of FL118 is not affected by ABCG2. A and D, Western blot
analysis of ABCG2 protein expression in HCT116-A2 cells that were stably transduced with a non-silencing shRNA control (ns) or anti-ABCG2 shRNA
(sh1 = V3LHS_380805, sh2 = V3LHS_380806) (A), and HEK293 cells that were stably transfected with either an ABCG2 expression vector
(HEK293/ABCG2) or a corresponding empty vector (HEK293/pcDNA3) (D). B and C, dose-response curves of SN-38 (B) and FL118 (C) after
72-hour treatments in HCT116-A2 cell lines. E and F, dose-response curves of SN-38 (E) and FL118 (F) after 72-hour treatments in HEK293 cell
lines that were stably transfected with ABCG2 expression vector or empty vector. Viability was determined as in Figure 1. Error bars = SEM, n = 3
independent experiments.
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FL118, or 7-allyl-FL118 with the addition of Ko143, we
were able to observe a significant decrease in EC50 for
7-bromomethyl-FL118 (87.0 nM to 17.0 nM, p <
0.0001), 7-chloromethyl-FL118, (26.8 nM to 12.9 nM,
p = 0.016), and 7-hydroxymethyl-FL118 (24.2 nM to 4.8
nM, p < 0.0001) (Table 2). Thus, the potency of the lat-
ter three FL118 analogues is affected by ABCG2 activ-
ity. We next compared the electronegativity (χ, in
Pauling units) of each added functional group to the ra-
tio of EC50 / EC50 + Ko143 (Figure 4B). Consistent with
the data shown in Table 2, it was revealed that chemical
groups with stronger electronegativity (bromomethyl,chloromethyl, and hydroxymethyl) show higher affinity to
ABCG2 than the chemical groups with weaker or no elec-
tronegativity (methyl, ethyl, and allyl) (Figure 4B). To-
gether, our work revealed that lack of polar functional
groups on the B ring of FL118 plays a role in FL118
bypassing ABCG2-mediated drug resistance.
Discussion
The present study expands the uniqueness of FL118 in
mechanism of action to overcome drug resistance, and
demonstrated that, in a panel of colon cancer and
NSCLC cell lines, FL118 is more potent than SN-38. We
found that, in contrast to the two clinically used
Westover et al. Molecular Cancer  (2015) 14:92 Page 6 of 11camptothecin analogues (irinotecan, topotecan), which
are ABCG2 substrates and unable to overcome ABCG2
resistance, FL118 potency is not affected by ABCG2 ex-
pression and can bypass ABCG2-mediated treatment
resistance. This phenomenon was investigated and con-
firmed by multiple independent approaches to either in-
hibit (i.e., pharmacological and genetic inhibition) or
enhance (i.e., overexpression) ABCG2 activity. These
approaches demonstrated that high ABCG2 activity re-
sults in resistance to SN-38 and topotecan, but not
FL118.
We also assessed the efficacy of FL118 in two distinct
in vivo xenograft models of ABCG2-mediated drug-
resistant cancer. In both models, FL118 exhibited a better
ability to decrease tumor growth in comparison with irino-
tecan, while maintaining a tolerable toxicity profile similar
to that of irinotecan. Most importantly, mice treated with
FL118 showed a significant increase in time to progression
(TTP) compared to mice treated with irinotecan.
Our group recently reported on the in vivo efficacy of
FL118 in other models of human cancer, using an intra-
venous (IV)-compatible, Tween/polysorbate 80-free
formulation [29]. In that study, we compared threeFigure 3 FL118 shows improved efficacy in two in vivo models of irinote
HCT116-SN50 or H460 subcutaneous xenografts with an average volume
irinotecan or 1.5 mg/kg FL118, on a repeating treatment for 4 weeks follo
progressed and were removed from treatment as tumor volume reached 150
HCT116-SN50 (A) and H460 (B) xenografts during treatment with either FL11
treatment, their final tumor volume was included in the graphed average
and D, Kaplan-Meier chart of progression events for animals with HCT116
progression between the two treatments was determined using the log-r
Error bars = SEM.schedules (every day for five injections, every other day
for five injections and once weekly for 4 injections) of
FL118 administration via IV administration. We found
that the optimum administration of FL118 appears to be
every other day. However, for this study, we opted for a
weekly schedule that mimics irinotecan administration
in the clinic. Therefore, while our results in this study
revealed that the weekly administration of FL118 was
able to significantly extend TTP in comparison with iri-
notecan, we predict that treating with FL118 every other
day for five treatments will show even better efficacy.
Additionally, in the current studies, we used IP routes
instead of intravenous administration of FL118 for tech-
nical convenience. However, the Tween/polysorbate 80-
free formulation of FL118 can be administrated via IV
routes with increased maximum tolerated dose (MTD).
This may also result in better in vivo tumor inhibition
outcomes for FL118. We intend to perform these experi-
ments with optimal routes and schedules in our follow-
up studies as part of a broader goal of optimizing FL118
administration to prepare for clinical applications.
It was reported that the affinity of camptothecin ana-
logues to ABCG2 is influenced by polar additions to thecan-resistant cancer in comparison with irinotecan. SCID mice bearing
of ~100 mm3 were treated via IP once per week with 100 mg/kg
wed by 1 week of rest. Individual animals were considered to have
0 mm3 or for a moribund condition. A and B, tumor growth curves for
8 or irinotecan. As individual mice progressed and were removed from
on subsequent dates. Each treatment is indicated with a caret. C
-SN50 (C) and H460 (D) xenografts. Statistical difference in time to
ank test. E and F, average body weight over time during treatments.
Figure 4 Electronegative potentials influence the affinity of the Position 7-substituted FL118 analogues for ABCG2 binding. A, structures of FL118
analogues with B ring substitutions. B, correlation between electronegativity of chemical groups (χ, Pauling units, calculated using the method of
Huheey) and the ratio of EC50 of drug alone / EC50 drug + Ko143.
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ring-substituted functional groups of FL118 may also
affect ABCG2 binding. To test this hypothesis, we mod-
eled the distinct electrostatic potential of six FL118 ana-
logues with different chemical groups on the 7-position
of the B ring versus FL118 itself, and assessed their po-
tency using cell proliferation assays. As before, we used
potency in the presence and absence of ABCG2 inhib-
ition as a surrogate for assessing the affinity of individual
drugs for ABCG2. We saw a significant change in EC50
in the presence of Ko143 for FL118 analogues with
stronger electronegative groups, indicating that these
FL118 analogues are substrates of ABCG2. We also
noted that some structures with less polar functional
groups (e.g., 7-ethyl-FL118) still have regions of localized
electronegativity in those groups (indicated by the redTable 2 Electronegativities (χ, Pauling units) for added 7-posi
SN50 cells
Compound χa χb χc EC50 (95% CI)
FL118 - - - 4.04 (2.79-5.86)
7-Methyl-FL118 2.27 2.47 2.40 1.49 (1.05-2.12)
7-Ethyl-FL118 2.28 2.48 2.43 2.43 (1.63-3.63)
7-Allyl-FL118 2.37 2.48 2.46 5.25 (2.71-10.2)
7-Bromomethyl-FL118 2.40 2.50 2.51 87.0 (53.0-142)
7-Chloromethyl-FL118 2.47 2.53 2.54 26.8 (14.0-51.2)
7-Hydroxymethyl-FL118 2.74 2.59 2.52 24.2 (16.8-34.7)
a. Huheey 1965 [37], 1966 [38], b. Inamoto 1982 [39], c. Wu 1999 [40].
95% CI = 95% confidence interval.gradient) (Additional file 1: Figure S5), while some struc-
tures with more polar groups lack such regions of mod-
erate localized electronegativity (e.g., 7-chloro-FL118,
Additional file 1: Figure S5). Comparing these electro-
static potential maps to our results in Table 2, we
propose that these localized electronegative regions are
less predictive of a compound’s affinity for ABCG2 than
the Pauling electronegativity of the molecule as a whole.
We recently reported a novel IV-compatible Tween/poly-
sorbate 80-free formulation for FL118, which could increase
FL118 MTD 3-7 fold in comparison with FL118 formulated
using the previous Tween/polysorbate 80-containing recipe
[29]. We found that in this new formulation, while
FL118 showed solubility similar to 7-bromomethyl-
FL118, 7-chloromethyl-FL118 and 7-hydroxymethyl-
FL118, the solubility of 7-methyl-FL118, 7-ethyl-FL118tion functional groups, and EC50 +/- K0143 in HCT116-
EC50 + Ko143 (95% CI) P Ratio EC50/EC50 + Ko143
3.02 (2.08-4.49) 0.22 1.34
1.11 (0.80-1.54) 0.20 1.34
1.85 (1.38-2.48) 0.22 1.31
4.07 (2.93-5.65) 0.42 1.29
17.0 (13.2-23.8) < 0.0001 5.12
12.9 (9.92-16.7) 0.016 2.08
4.79 (3.87-5.92) < 0.0001 5.05
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larly, FL118 analogues with other 7-substituted nonpo-
lar groups (e.g., cycloalkyl, aryl) also showed poor
solubility in our Tween/polysorbate 80-free formulation
recipes with or without 5% DMSO. Therefore, future
studies related to the structural modification of the
FL118 scaffold should be based on the findings revealed
from these compounds to further optimize potency and
drug-like properties, for example by adding hydrophilic
group on positions of 5, 9 or 12. Alternatively, we may
generate the pro-drug for potent compounds, such as di-
peptide derivatives to increase water solubility. Working in
these directions may allow us to generate compounds with
even better therapeutic index (TI, i.e. ratio of antitumor ac-
tivity versus toxicity) than the favorable TI of FL118 [29].
Here, it should be pointed out that the relationship be-
tween the affinity of camptothecin analogues to ABCG2
and the strength of electronegative charges of distinct
chemical groups on the B ring has not been investigated
previously, although the B ring of camptothecin is often
modified in order to improve the anticancer potency and
pharmacological properties [25,26]. While there was a posi-
tive correlation between χ and ABCG2-induced resistance,
the large loss of potency for 7-bromomethyl-FL118
compared to 7-chloromethyl-FL118 suggests that func-
tional group electronegativity may be only one characteris-
tic that influences ABCG2 affinity. Since ABCG2-mediated
resistance to anticancer drugs, including irinotecan and
topotecan, is a recognized problem in the clinic, further un-
derstanding of the structure-activity relationship of FL118
analogues for ABCG2 binding may lead to rational design
of better anticancer agents for clinical application.
Interestingly, cabazitaxel, a taxane derivative with
poor affinity for another drug-efflux pump protein, P-
glycoprotein 1 (P-gp, also known as multidrug resist-
ance protein 1 and ABCB1), was recently approved for
use in patients with castration-resistant prostate cancer
who had previously failed docetaxel-based regimens
[30]. It is thought that cabazitaxel’s lack of affinity for
P-gp plays an important role in its effectiveness in
docetaxel-refractory cancer. In keeping with this ration-
ale, the work presented here suggests that this strategy
may be useful in other cancer types and with other
classes of cytotoxic agents, including camptothecins.
Due to FL118’s superior anticancer activity, favorable
tolerability, and insensitivity to ABCG2, we posit that
FL118 may become a better option for targeted cancer
therapeutics to address the increasingly complex issue
of drug failure by circumventing multiple mechanisms
of drug resistance, including efflux pump-mediated
resistance.
In conclusion, the present study demonstrated that
FL118 has additional mechanistic features in terms of its
superior anticancer efficacy, which further distinguish itfrom irinotecan, SN-38 and topotecan. These findings
suggest that FL118 is a poor substrate for the drug efflux
pump ABCG2, and thus FL118 is able to overcome
ABCG2-mediated resistance to SN-38, irinotecan and
topotecan in vitro and in vivo. Additionally, this study
also indicated that polar chemical groups on the B ring
of FL118 analogues can contribute to ABCG2-mediated
resistance, which provides one principle for new FL118
analogue design. Together, the new features of FL118 re-
vealed in this study plus the other FL118 unique features
reported in our previous studies warrants FL118 further
development toward clinical application.
Materials and methods
Drug resource and preparation
Topotecan (Selleckchem Chemicals, Houston, TX), FL118
(in house), and FL118 analogues (RTI International) were
prepared as stocks at 1 mM in DMSO (Merck KGaA,
Darmstadt, Germany). The synthesis of FL118 and FL118
analogues (7-methyl-FL118, 7-ethyl-FL118, 7-allyl-FL118,
7-bromomethyl-FL118, 7-chloromethyl-FL118 and 7-hydro
xymethyl-FL118) were reported previously [21,31,32]. Stock
SN-38 (Sigma-Aldrich Corporation, St. Louis, MO) was
prepared at 2.5 mM in DMSO. Ko143 (Tocris Bioscience,
Bristol, United Kingdom) was prepared as stock solutions
at 10 mM in DMSO.
Cell culture
Human colorectal cancer cell lines HCT8, HCT116, and
SW620 and NSCLC cell lines A549 and NCI-H460
(“H460”) were purchased from American Type Culture
Collection (ATCC, Manassas, VA). The human NSCLC
cell line EKVX (donated by Dr. Daniel Chan) was originally
from the National Cancer Institute [33]. Camptothecin re-
sistant sub-lines of HCT116 with mutated Top1 (HCT116-
SN6, HCT116-G7, HCT116-A2, and HCT116-SN50) were
established and described previously by Drs. Gongora and
Del Rio [10]. Drug resistant cell lines were passaged in 10
nM SN-38, except for five days prior to all experiments, to
maintain resistant phenotypes. Human embryonic kidney
HEK293 cells that were stably transfected with either an
ABCG2 expression vector (HEK293/ABCG2) or an empty
vector (HEK293/pcDNA3) were provided by Dr. Wendy
Huss, which were originally a gift fromDr. Susan Bates (Na-
tional Cancer Institute, Rockville, MD). All cell lines were
maintained in RPMI-1640medium supplemented with 10%
heat-inactivated fetal bovine serum, 100 U/mL penicillin,
and 0.1 μg/mL streptomycin (“complete media”). Cells were
cultured in 5 % CO2 at 37°C and passaged every 2-4 days.Immunoblot analysis
Immunoblot analysis was performed as described previ-
ously [34], with minor modifications. Briefly, cells were
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(50 mM Tris, 150 mM NaCl, 0.1% SDS, 0.5% sodium
deoxycholate, 1% Nonidet P-40, 10 μg/mL PMSF,
20 μM leupeptin) and sonicated for 15 s using a sonic
dismembrator 100 (Thermo Fisher Scientific, Waltham,
MA) to homogenize lysate. Next, lysate was denatured
with 5X Laemmli Sample Buffer (5X: 300 mM Tris-HCl
pH 6.8, 10% SDS, 50% glycerol, 20% β-mercaptoethanol,
0.05% bromophenol blue) and equal amounts of protein
were electrophoretically separated on 10-15% SDS-
PAGE gels and electrotransferred onto 0.2 μm nitro-
cellulose membranes (Bio-Rad Laboratories, Inc.,
Hercules, CA). Membranes were blocked for 1 h at
room temperature in 5% skim milk, then incubated
with primary antibody (1:1,000 for ABCG2 and 1:5,000
for actin) in 5% bovine serum albumin in TBS-T over-
night at 4°C. Membranes were washed with TBS-T,
then incubated with species-specific anti-IgG anti-
bodies conjugated to horseradish peroxidase (1:5,000,
second antibody) at room temperature for 1 h in 5%
milk. Membranes were again washed with TBS-T.
Chemiluminescence with ECL plus (PerkinElmer, Inc.,
Waltham, MA) was used to detect protein using X-ray
film (Midsci, St. Louis, MO).Cell proliferation and viability assay
Cells were plated in 6-well plates at densities ranging from
2 x 105 to 4 x 105 cells per well, depending on doubling
time. On day 2, cells were treated with varying concentra-
tions of indicated compounds in complete media. Final
concentration of the vehicle, DMSO, was 0.1% in all treat-
ments with or without drugs. On day 5, attached cells were
harvested with 0.5 mL of 0.25% Trypsin-EDTA. Trypsin
was deactivated by addition of 0.5 mL of complete media
and cells were analyzed on a Vi-CELL XR Cell Viability
Analyzer (Beckman Coulter Inc., Brea, CA). EC50 values
and coefficient of determination (R2) were calculated from
seven doses of each analyzed compound, in addition to the
vehicle control, using GraphPad Prism 6 (GraphPad Soft-
ware, Inc., La Jolla, CA). Each experiment was performed
at least 3 times.
Transduction of lentiviral particles containing ABCG2-
specific or control shRNA
Lentiviral particles containing ABCG2-specific shRNA, with
sequences of AACTCTTGAATGACCCTGT (V3LHS_
380805) or ATAATACTTGGTAACATCC (V3LHS_
380806), and one control non-silencing shRNA
(Dharmacon, Lafayette, CO) were prepared in the
Rowell Park Cancer Institute shRNA Core Facility as
previously described [18]. HCT116-SN50 cells were
plated in 6-well plates at a density of 7 x 105 cells/
well. The next day, media was aspirated and 0.5 mLof fresh complete media and 0.5 mL of viral super-
natant were added to each well. Cells were incubated
with viral supernatant in 5% CO2 at 37°C for 16 h.
Stably transduced cells were selected and maintained
in 1 μg/mL puromycin (Invivogen, San Diego, CA).
Electrostatic potential maps
Electrostatic potential maps were generated using the
PBEQ solver module [35] in CHARMM-GUI [36] in de-
fault conditions, using protein data bank (.pdb) files and
Tripos Mol2 (.mol2) files created with MarvinSketch
14.7.7.0 (ChemAxon, Ltd., Budapest, Hungary). Maps
were visualized with PyMOL 1.3r1 edu (Schrödinger,
LLC, New York, NY).
Pauling electronegativity
Electronegativities were taken from published studies
[37-40]. When electronegativities for certain functional
groups were not reported in those studies, they were cal-
culated using the methods developed by the authors in
the cited works [37-40].
Establishment of human xenograft models
Xenografts were established in female 12-week old
severe combined immunodeficiency (SCID) mice. Cells
(4 x 106 per injection) were suspended in 200 μL of a 1:1
solution of ice-cold serum-free RPMI 1640 media and
matrigel (Corning Incorporated, Corning, NY) and
injected subcutaneously into the left flank. When tumors
reached an average volume of 100 mm3, animals were ran-
domly assigned to one of two treatment groups. One
group received 100 mg/kg irinotecan (Camptosar) (Pfizer,
New York, NY), the MTD, IP once per week. The other
group received the MTD of FL118, 1.5 mg/kg, IP once per
week. The treatment schedule, one treatment per week for
4 weeks, followed by 1 week of rest, repeated until pro-
gression, was selected to approximate the administration
of camptothecin-class drugs in the clinic [41,42]. Tumor
volume and body weight were measured three times per
week. Progression was defined as a tumor volume ≥
1500 mm3 or a moribund condition. Tumor volume was
calculated as V = 0.5*(length x width2), and was measured
using digital calipers.
Statistical analysis
An extra sum-of-squares F test was used to compare
dose response curves. Comparison of survival curves for
xenograft models was done using the log-rank test. To
assess the difference between calculated RR values in
camptothecin-resistant HCT116 sublines, which had
logarithmic error, the RR value was back-transformed to
LogRR so that the error would be symmetric. The
LogRR values for FL118 and SN-38 were then compared
using Student’s t-test. A p-value of ≤ 0.05 was considered
Westover et al. Molecular Cancer  (2015) 14:92 Page 10 of 11significant for all analyses. Power analysis to determine
appropriate group sizes for in vivo work was done with
the following parameters: α = 0.05, power = 0.8.Study approval
All studies using animals were approved by the Institu-
tional Animal Care and Use Committee (IACUC) at
Roswell Park Cancer Institute.Additional file
Additional file 1: Figure S1. Structure of camptothecin, FL118, and
clinically relevant camptothecin analogues (irinotecan, SN-38, topotecan) is
shown. The conventional ring nomenclature of camptothecin is denoted.
Figure S2. Dose-response graphs for FL118 in a panel of cancer cell lines.
Cells analyzed after 72-hour treatment. Viability for each dose was determined
using a ViCELL XR cell viability analyzer and normalized to that of DMSO
control. EC50 and coefficient of determination (R2) calculated using GraphPad.
Error bars = SEM, n = 3 independent experiments. Figure S3. Dose-response
graphs for SN-38 in a panel of cancer cell lines. Cells analyzed after 72-hour
treatment. Viability, EC50, and R2 were determined as in Figure S2. Error
bars = SEM, n = 3 independent experiments. Figure S4. Pharmacological
inhibition of ABCG2 modulates potency of topotecan. Dose-response curve
of topotecan in the presence and absence of 1 μM Ko143 after 72-hour
treatment is shown. Viability determined as in Figure S2. Error bars = SEM,
n = 3 independent experiments. Figure S5. Electrostatic potential maps of
FL118 and its analogues. Maps were generated in the PBEQ solver module
of the CHARMM-GUI and visualized using PyMOL. The red and blue
gradient in each molecule as shown represents areas with least and
most electrostatic potential, respectively. The green arrows next to
7-ethyl-FL118 and 7-chloromethyl-FL118 point toward the added
functional group and highlight the difference in localized electrostatic
potential discussed in the text. Table S1. LogEC50 and LogRR of
FL118 and SN-38 in HCT116 colorectal cancer cell lines and Top1
inhibitor-resistant HCT116 sub-lines. Table S2. EC50 of FL118 and
SN-38 in cells with genetically altered ABCG2 expression.Abbreviations
NSCLC: non-small cell lung cancer; Top1: Topoisomerase I; ABC: ATP-binding
cassette protein; IP: Intraperitoneal; IV: Intravenous; RR: Relative resistance;
TI: Therapeutic index.
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